The Council for the Advancement of Diabetes Research and Education (CADRE) is a nonprofit organization committed to reducing the burden of diabetes by providing health care professionals with scientific information and educational initiatives designed to translate research into effective clinical practice.
Effectively managing diabetes requires both day-to-day disease management and up-to-date information on new discoveries and evolving therapies. CADRE has developed a wide-range of diabetes-related programming and materials to help healthcare professionals stay on top of new information, including:
- The CADRE Handbook of Diabetes Management
- CADRE's Current Diabetes Practice, the official CADRE newsletter
- Diabetes slides for use in lecture programs or as self-education resources
- CADRE Symposia and other live continuing medical education diabetes programs
These CADRE diabetes programs support, highlight, and promote practical guidelines for patient education and management as well as cutting-edge research in diabetes pathophysiology and treatment by addressing such issues as:
- Epidemiology, etiology, and pathophysiology of both type 1 and type 2 diabetes
- Intensive therapeutic guidelines and management strategies to reduce complications of diabetes
- Patient education and self-management
- Treatment options for type 1 and type 2 diabetes
- Trends in diabetes research
CADRE receives funding for its educational activities from multiple sources, including Amylin Pharmaceuticals, Amylin-Lilly, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly & Company, GlaxoSmithKline, Johnson & Johnson, LifeScan, Merck & Co., Novartis, Novo Nordisk, Nutrition 21, Pfizer Inc, and sanofi-aventis.
